Tandem Diabetes Care (NASDAQ:TNDM) PT Raised to $40.00 at Stifel Nicolaus

Tandem Diabetes Care (NASDAQ:TNDM) had its target price upped by Stifel Nicolaus from $37.00 to $40.00 in a research note issued to investors on Tuesday, Benzinga reports. The firm presently has a “buy” rating on the medical device company’s stock. Stifel Nicolaus’ target price points to a potential upside of 13.90% from the stock’s previous close.

A number of other research firms also recently weighed in on TNDM. StockNews.com upgraded Tandem Diabetes Care from a “sell” rating to a “hold” rating in a research report on Friday, April 19th. Citigroup upped their price objective on Tandem Diabetes Care from $31.00 to $38.00 and gave the stock a “neutral” rating in a research report on Wednesday, April 3rd. One investment analyst has rated the stock with a sell rating, six have given a hold rating and five have assigned a buy rating to the company’s stock. According to MarketBeat, Tandem Diabetes Care has a consensus rating of “Hold” and a consensus price target of $37.27.

Tandem Diabetes Care Stock Performance

NASDAQ:TNDM opened at $35.12 on Tuesday. The stock has a fifty day moving average price of $30.51 and a 200-day moving average price of $25.18. The company has a market cap of $2.27 billion, a price-to-earnings ratio of -10.21 and a beta of 1.12. The company has a debt-to-equity ratio of 0.91, a quick ratio of 3.02 and a current ratio of 3.83. Tandem Diabetes Care has a fifty-two week low of $13.82 and a fifty-two week high of $40.74.

Tandem Diabetes Care (NASDAQ:TNDM) last released its earnings results on Wednesday, February 21st. The medical device company reported ($0.27) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.23) by ($0.04). The company had revenue of $196.80 million for the quarter, compared to the consensus estimate of $204.86 million. Tandem Diabetes Care had a negative net margin of 29.77% and a negative return on equity of 31.48%. As a group, equities analysts anticipate that Tandem Diabetes Care will post -1.62 EPS for the current fiscal year.

Hedge Funds Weigh In On Tandem Diabetes Care

Several large investors have recently bought and sold shares of the company. Assenagon Asset Management S.A. acquired a new stake in shares of Tandem Diabetes Care in the first quarter valued at about $8,018,000. New Mexico Educational Retirement Board acquired a new stake in shares of Tandem Diabetes Care in the first quarter valued at about $460,000. Arcadia Investment Management Corp MI increased its stake in shares of Tandem Diabetes Care by 141.6% in the first quarter. Arcadia Investment Management Corp MI now owns 1,851 shares of the medical device company’s stock valued at $66,000 after buying an additional 1,085 shares during the period. Allspring Global Investments Holdings LLC increased its stake in shares of Tandem Diabetes Care by 1,567.1% in the first quarter. Allspring Global Investments Holdings LLC now owns 6,635 shares of the medical device company’s stock valued at $235,000 after buying an additional 6,237 shares during the period. Finally, Diversified Trust Co increased its stake in shares of Tandem Diabetes Care by 24.6% in the first quarter. Diversified Trust Co now owns 13,173 shares of the medical device company’s stock valued at $466,000 after buying an additional 2,600 shares during the period.

About Tandem Diabetes Care

Tandem Diabetes Care, Inc, a medical device company, designs, develops, and commercializes technology solutions for people living with diabetes in the United States and internationally. The company's flagship product is the t:slim X2 insulin delivery system, a pump platform for managing insulin delivery and display continuous glucose monitoring sensor information directly on the pump home screen; and Tandem Mobi insulin pump, an automated insulin delivery system.